Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SNP-610
- Development stage
- Phase 2
- Lead developer
- Sinew Pharma
- Modality
- Small Molecules, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Oral
01
Overview
SNP-610 is a first-in-class small molecule drug under development by Sinew Pharma for the treatment of non-alcoholic steatohepatitis (NASH), also known as metabolic dysfunction-associated steatohepatitis (MASH). The drug acts primarily by inhibiting diacylglycerol O-acyltransferase 1 (DGAT1), cytochrome P450 2E1 (CYP2E1), and hormone-sensitive lipase enzymes. Its mechanism involves impeding triglyceride synthesis and accumulation, reducing fatty acid absorption in liver cells, decreasing reactive oxygen species (ROS) production, and inhibiting pro-fibrotic and pro-inflammatory factors through immune cell regulation. It is administered orally as a tablet. As of June 2023, SNP-610 has reached Phase II clinical trials in both Taiwan and the USA for NASH/MASH.
- Other names
- SNP 610SNP610SNP-610SN 610SN610SN-610
02
Targets
CYP2E1DGAT1 (Diacylglycerol O-acyltransferase 1)LIPE (Hormone-sensitive lipase)
Beyond the preview
Go deeper on SNP-610.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SNP-610.